Roos, I. Et Al. 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal .

Roos, I., Sharmin, S., Malpas, C., Ozakbas, S., Lechner-Scott, J., Hodgkinson, S., ... Alroughani, R.(2024). Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal .

Roos, Izanne Et Al. "Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis," Multiple Sclerosis Journal , 2024

Roos, Izanne Et Al. "Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis." Multiple Sclerosis Journal , 2024

Roos, I. Et Al. (2024) . "Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis." Multiple Sclerosis Journal .

@article{article, author={Izanne Roos Et Al. }, title={Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis}, journal={Multiple Sclerosis Journal}, year=2024}